APA (7th ed.) Citation

Geraghty, L., Schultz, T. E., Hoffman, S. E., Porter, K., Issa, M., Karivedu, V., & Bonomi, M. (2021). Weekly vs. 3-weekly paclitaxel, carboplatin, and cetuximab (PCC) in recurrent/metastatic head and neck cancer. Molecular & Clinical Oncology, 15(5), N.PAG. https://doi.org/10.3892/mco.2021.2403

Chicago Style (17th ed.) Citation

Geraghty, Leeann, Thomas E. Schultz, Sarah E. Hoffman, Kyle Porter, Majd Issa, Vidhya Karivedu, and Marcelo Bonomi. "Weekly Vs. 3-weekly Paclitaxel, Carboplatin, and Cetuximab (PCC) in Recurrent/metastatic Head and Neck Cancer." Molecular & Clinical Oncology 15, no. 5 (2021): N.PAG. https://doi.org/10.3892/mco.2021.2403.

MLA (9th ed.) Citation

Geraghty, Leeann, et al. "Weekly Vs. 3-weekly Paclitaxel, Carboplatin, and Cetuximab (PCC) in Recurrent/metastatic Head and Neck Cancer." Molecular & Clinical Oncology, vol. 15, no. 5, 2021, p. N.PAG, https://doi.org/10.3892/mco.2021.2403.